New Horizons in Robotic Surgery: DaVinci Begins to Compete

Abstract

The use of robotic technology in minimally invasive surgery has expanded worldwide in the last two decades. Currently being the DaVinci system of the Intuitive Surgical company, one of the most used in many surgical specialties within them, Urology. This system has obtained more than 1500 patents in the robotics area; however, some have already expired. Thus, allowing the development of new platforms as an alternative to the monopoly achieved by this system. Some robotic platforms in actual development feature a modular design, open console, smaller instruments (<8mm), and haptic feedback (tactile sensation). These new designs of robotic surgery technology highlight cost-effective systems, single port surgery, artificial intelligence formachine learning, but it should be noted that they face a long and complex process of clinical studies and approval by regulatory entities.1 The SENHANCE surgical system, approved by the Food and Drug Administration (FDA) since 2017, and the Korean robotic system REVO-I, also approved in 2017 for local usage, have been IntuitiveSurgical’s competitors andhadset thebeginning for other robotic surgery companies to be available at the market. With both systems, multiple abdominal procedures have been performed in general surgery, urology, and gynecology. The existingmedical literature to date shows that they are reliable instruments,withgoodresults in termsof safety, in addition to oncological or functional follow-up according to the pathology; comparable results with those obtained with the DaVinci system were demonstrated.2–4 Other robotic systems worth mentioning are the “German Robot” AVATERA and the Japanese Medicaroid robot HINOTORI. This last onewith amission that enhances Asimov’s laws of robotics “to serve and help humans, not replace humans.” The HINOTORI obtained its license for usage in 2020 by that country, but it still does not have preclinical studies or clinical data in humans, still in the development stage. It must be highlighted what two medical device companies have done as they launched robotic surgery facilities at different latitudes of theworld, each in their way, globalizing their market and starting the real competition for Intuitive. Those are Versius Surgical Robotic System CMR Surgical in the UK with installations in India, Australia, and their own country. The other is Medtronic, recognized as one of the giants in medical devices in the world; its robotic surgical system, HUGO, has systems already installed in Latin America, Panama, and Chile with surgical programs that successfully took off a few months ago at lower costs.5–7 There is a great expectation with the project created with the merge of two large companies, Johnson & Johnson and Google, VERB SURGICAL, several years working on their robotic system. However, they have not yet come to light with their device; It has been an airtight organization in terms of system development details, but this system is expected to compete with high-quality standards. Robotic-assisted surgery is here to stay. A significant limitation for its expansion has mainly been its high acquisition, maintenance, and operation costs. However, these new platforms are intended to be more accessible to all health systems worldwide so they can gain from the advantage of the well-known benefits of minimally invasive surgery. Worldwide, 6,335 units of the DaVinci system8 have been installed. Thus, reiterating this system’s reliability and exponential growth; even more, the search of using new technologies. DaVinci begins to compete with rivals of excellent quality and potential, leaving its previous monopoly to enter an era of new challenges to continue in the “game.”